person · Reporting owner
ODONNELL FRANCIS E JR
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | Director · Chief Executive Officer · 10% owner | May 04, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibitor Therapeutics, Inc.
Report date May 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,000 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 50,000 · Balance 150,000 F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIODELIVERY SCIENCES INTERNATIONAL INC
Report date May 11, 2020 · Filed May 14, 2020
Section 16 reporting ended · disclosed 2020-05-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 628,038 |
Reported balance
After 2020-05-11 transaction · row 1
1 source rowRow 1 · 2020-05-11 · Exercise / conversion · Acquired 22,500 · Balance 628,038 F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-05-11 | Direct | 0 |
Reported balance
After 2020-05-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-11 · Exercise / conversion · Disposed 22,500 · Balance 0 F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed Aug 4, 2026 15:55 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-035950 · ownership.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval. Read SEC document |
| May 11, 2020 Filed May 14, 2020 20:07 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 22,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000085 · wf-form4_158948682328123.xml · derivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. Read SEC document |
| May 11, 2020 Filed May 14, 2020 20:07 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000085 · wf-form4_158948682328123.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 11,250 | $4.53 | $50,962.50 |
DisclosureSEC source: 0001103021-20-000075 · wf-form4_158896837397701.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,538 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On May 6, 2020, the Reporting Person sold an aggregate of 11,250 shares of the Issuer's Common Stock at a weighted average price of $4.53 per share. The highest sale price for the Common Stock was $4.66 per share and the lowest sale price was $4.44 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 16,000 | $4.45 | $71,200.00 |
DisclosureSEC source: 0001103021-20-000064 · wf-form4_158870918252713.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,788 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On May 4, 2020, the Reporting Person sold an aggregate of 16,000 shares of the Issuer's Common Stock at a weighted average price of $4.45 per share. The highest sale price for the Common Stock was $4.56 per share and the lowest sale price was $4.39 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 20,000 | $4.22 | $84,400.00 |
DisclosureSEC source: 0001103021-20-000058 · wf-form4_158758670274343.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,788 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On April 20, 2020, the Reporting Person sold an aggregate of 20,000 shares of the Issuer's Common Stock at a weighted average price of $4.22 per share. The highest sale price for the Common Stock was $4.29 per share and the lowest sale price was $4.15 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 30,500 | $3.63 | $110,715.00 |
DisclosureSEC source: 0001103021-20-000052 · wf-form4_158456269796322.xml · nonDerivative · entry 7 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,072 F6 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F7 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F9 · price: On March 17, 2020, the Reporting Person sold an aggregate of 30,500 shares of the Issuer's Common Stock at a weighted average price of $3.63 per share. The highest sale price for the Common Stock was $3.81 per share and the lowest sale price was $3.39 per share. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000052 · wf-form4_158456269796322.xml · derivative · entry 9 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2021. F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2021. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 62,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000052 · wf-form4_158456269796322.xml · derivative · entry 8 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,500 shares Expires 2020-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended, (the EIP). F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended, (the EIP). Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 38,750 | $3.60 | $139,500.00 |
DisclosureSEC source: 0001103021-20-000052 · wf-form4_158456269796322.xml · nonDerivative · entry 6 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,572 F6 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F7 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F8 · price: On March 16, 2020, the Reporting Person sold an aggregate of 38,750 shares of the Issuer's Common Stock at a weighted average price of $3.60 per share. The highest sale price for the Common Stock was $3.72 per share and the lowest sale price was $3.46 per share. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 18,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000052 · wf-form4_158456269796322.xml · nonDerivative · entry 5 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,322 F5 · kind: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of 18,284 RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. F5 · price: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of 18,284 RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000052 · wf-form4_158456269796322.xml · nonDerivative · entry 4 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,470 F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2021 subject to certain performance measures. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2021 subject to certain performance measures. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000052 · wf-form4_158456269796322.xml · nonDerivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2021. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2021. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000052 · wf-form4_158456269796322.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 673,754 F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:18 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000052 · wf-form4_158456269796322.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended, (the EIP). F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended, (the EIP). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:21 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $5.31 | $42,480.00 |
DisclosureSEC source: 0001103021-20-000026 · wf-form4_158086206019120.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On February 3, 2020, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $5.31 per share. The highest sale price for the Common Stock was $5.38 per share and the lowest sale price was $5.12 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:23 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $6.10 | $48,800.00 |
DisclosureSEC source: 0001103021-20-000002 · wf-form4_157808658444249.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On January 2, 2020, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $6.10 per share. The highest sale price for the Common Stock was $6.30 per share and the lowest sale price was $5.86 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 22:40 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 10,000 | $7.00 | $70,000.00 |
DisclosureSEC source: 0001103021-19-000059 · wf-form4_157774563169597.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On December 26, 2019, the Reporting Person sold an aggregate of 10,000 shares of the Issuer's Common Stock at a weighted average price of $7.00 per share. The highest sale price for the Common Stock was $7.01 per share and the lowest sale price was $7.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| December 26, 2019 Filed Dec 31, 2019 21:20 UTC Amendment | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionStock Options (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001103021-19-000061 · wf-form4a_157782723730257.xml · derivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4/A amends the Reporting Person's Form 4 filed on December 30, 2019 to reflect that the shares of Common Stock were sold following the automatic exercise of the Reporting Person's stock options (right to buy). Read SEC document |
| December 26, 2019 Filed Dec 31, 2019 21:20 UTC Amendment | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 10,000 | $7.00 | $70,000.00 |
DisclosureSEC source: 0001103021-19-000061 · wf-form4a_157782723730257.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,754 F1 · security: This Form 4/A amends the Reporting Person's Form 4 filed on December 30, 2019 to reflect that the shares of Common Stock were sold following the automatic exercise of the Reporting Person's stock options (right to buy). Read SEC document |
| December 26, 2019 Filed Dec 31, 2019 21:20 UTC Amendment | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 10,000 | $1.96 | $19,600.00 |
DisclosureSEC source: 0001103021-19-000061 · wf-form4a_157782723730257.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4/A amends the Reporting Person's Form 4 filed on December 30, 2019 to reflect that the shares of Common Stock were sold following the automatic exercise of the Reporting Person's stock options (right to buy). Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:13 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $6.86 | $54,880.00 |
DisclosureSEC source: 0001103021-19-000048 · wf-form4_157549397191205.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On December 2, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $6.86 per share. The highest sale price for the Common Stock was $6.96 per share and the lowest sale price was $6.71 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:31 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $5.83 | $46,640.00 |
DisclosureSEC source: 0001103021-19-000027 · wf-form4_157298947575370.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 572,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On November 1, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $5.83 per share. The highest sale price for the Common Stock was $5.94 per share and the lowest sale price was $5.72 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 20:33 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionStock Options (right to buy) · Derivative | 32,500 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001103021-19-000025 · wf-form4_157246762155802.xml · derivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2021-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 20:33 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 32,500 | $6.00 | $195,000.00 |
DisclosureSEC source: 0001103021-19-000025 · wf-form4_157246762155802.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,754 F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 20:33 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 32,500 | $3.47 | $112,775.00 |
DisclosureSEC source: 0001103021-19-000025 · wf-form4_157246762155802.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 21:26 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionStock Options (right to buy) · Derivative | 32,500 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001103021-19-000020 · wf-form4_157134757985548.xml · derivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2020-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 21:26 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 32,500 | $5.00 | $162,500.00 |
DisclosureSEC source: 0001103021-19-000020 · wf-form4_157134757985548.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,754 F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. F2 · security: On October 15, 2019, the Reporting Person sold an aggregate of 32,500 shares of the Issuer's Common Stock at a weighted average price of $5.00 per share. The highest sale price for the Common Stock was $5.02 per share and the lowest sale price was $5.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 21:26 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 32,500 | $2.26 | $73,450.00 |
DisclosureSEC source: 0001103021-19-000020 · wf-form4_157134757985548.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $4.34 | $34,720.00 |
DisclosureSEC source: 0001103021-19-000017 · wf-form4_157013349492572.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On October 1, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $4.34 per share. The highest sale price for the Common Stock was $4.40 per share and the lowest sale price was $4.28 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 20:08 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $4.29 | $34,320.00 |
DisclosureSEC source: 0001103021-19-000011 · wf-form4_156762767454014.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On September 3, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $4.29 per share. The highest sale price for the Common Stock was $4.35 per share and the lowest sale price was $4.19 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 20:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $3.82 | $30,560.00 |
DisclosureSEC source: 0001628280-19-009862 · wf-form4_156477635945465.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On August 1, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $3.82 per share. The highest sale price for the Common Stock was $3.94 per share and the lowest sale price was $3.67 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $4.68 | $37,440.00 |
DisclosureSEC source: 0000899243-19-019205 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On July 1, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $4.68 per share. The highest sale price for the Common Stock was $4.75 per share and the lowest sale price was $4.63 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $4.32 | $34,560.00 |
DisclosureSEC source: 0000899243-19-015636 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,754 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On June 3, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $4.32 per share. The highest sale price for the Common Stock was $4.42 per share and the lowest sale price was $4.26 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| May 09, 2019 Filed May 10, 2019 22:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-013105 · doc4.xml · derivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2020-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 of Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended . The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Quarterly Report for March 31, 2020. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 of Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended . The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Quarterly Report for March 31, 2020. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 of Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended . The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Quarterly Report for March 31, 2020. Read SEC document |
| May 09, 2019 Filed May 10, 2019 22:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 22,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-013105 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 of Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended . The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Quarterly Report for March 31, 2020. Read SEC document |
| May 01, 2019 Filed May 3, 2019 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $4.77 | $38,160.00 |
DisclosureSEC source: 0000899243-19-012060 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,254 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On May 1, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $4.77 per share. The highest sale price for the Common Stock was $4.85 per share and the lowest sale price was $4.69 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0000899243-19-010939 · doc4.xml · derivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-04-17 F2 · derivative.exercise_date: The stock options ("options") were issued to the Reporting Person on April 17, 2019, as compensation for service on the Issuer's board of directors. The options vest as follows: (i) 11,250 options vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, and (ii) 11,250 RSUs vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. The exercise price of the options is the volume-weighted average price of the Issuer's Common Stock for the 30-day period ending April 16, 2019. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 45,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-010939 · doc4.xml · derivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2020-05-09 F1 · derivative.exercise_date: The restricted stock units ("RSUs") were issued to the Reporting Person on April 17, 2019, as compensation for service on the Issuer's board of directors. The RSUs vest as follows: (i) 22,500 RSUs vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, and (ii) 22,500 RSUs vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $5.19 | $41,520.00 |
DisclosureSEC source: 0000899243-19-009828 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,254 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On April 1, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $5.19 per share. The highest sale price for the Common Stock was $5.34 per share and the lowest sale price was $5.12 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 71,690 | $5.21 | $373,504.90 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · nonDerivative · entry 6 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,254 F7 · security: The shares of Common Stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F8 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in these footnotes. F6 · price: On March 21, 2019, the Reporting Person sold an aggregate of 71,690 shares of the Common Stock at a weighted average price of $5.21 per share. The highest sale price for the Common Stock was $5.33 per share and the lowest sale price was $5.04 per share. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 9,757 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · derivative · entry 11 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,757 shares Expires 2019-03-20 F5 · kind: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. F5 · derivative.exercise_date: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · derivative · entry 10 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-03-19 F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · derivative · entry 9 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 15,000 shares Expires 2021-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021. F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 62,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · derivative · entry 8 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,500 shares Expires 2020-03-19 F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 62,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · derivative · entry 7 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2020-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 9,757 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · nonDerivative · entry 5 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,944 F5 · kind: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. F5 · price: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · nonDerivative · entry 4 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676,187 F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · nonDerivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,187 F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.